Interactions Hôte-Greffon-Tumeur & Ingénierie Cellulaire et Génique

Recent papers from Interactions Hôte-Greffon-Tumeur & Ingénierie Cellulaire et Génique

1. Economic burden of hospital admissions for adverse drug reactions in France: The IATROSTAT‐ECO studyBritish Journal of Clinical Pharmacology · 2024
2. Discovery of New Highly Potent Histamine H₃ Receptor Antagonists, Calcium Channel Blockers, and Acetylcholinesterase InhibitorsACS Chemical Neuroscience · 2024
3. Imaging-Based Drug Penetration Profiling in an Excised Sheep Cornea ModelPharmaceutics · 2024
4. Efficacy of the PEN-FAST score in a French cohort of patients with reported allergy to penicillinsFrontiers in Allergy · 2024
5. A Mimicry-Based Strategy Between Human and Commensal Antigens for the Development of a New Family of Immune Therapies for Cancer2024
6. Pos0865 Safety and Effectiveness of Avacopan Beyond 52 Weeks: Experience to Date in the Early Access Program (Eap)2024
7. Real-world outcomes of combined lenvatinib and anti-PD-1 in advanced melanoma: Lenvamel, a multicenter retrospective study of the French Group of Skin Cancers.Journal of Clinical Oncology · 2024
8. Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEXAnnals of the Rheumatic Diseases · 2024
9. Development and validation of a HPLC method simultaneously assisted with diode array and evaporative light scattering detection for the quantification of clinical mAb infusion bags in hospital pharmacyJournal of Liquid Chromatography &amp Related Technologies · 2024
10. #2256 Safety and effectiveness of avacopan beyond 52 weeks: experience to date in the Early Access Program (EAP)Nephrology Dialysis Transplantation · 2024
11. Targeting two radiation-induced immunosuppressive pathways to improve the efficacy of normofractionated radiation therapy in a preclinical colorectal cancer modelInternational Journal of Radiation Biology · 2024
12. Long‐term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO)British Journal of Haematology · 2024
13. Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients’ Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC)Cancers · 2023